A Randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction - The Air Primary Angioplasty in Myocardial Infarction study

被引:254
作者
Grines, CL [1 ]
Westerhausen, DR
Grines, LL
Hanlon, JT
Logemann, TL
Niemela, M
Weaver, WD
Graham, M
Boura, J
O'Neill, WW
Balestrini, C
机构
[1] William Beaumont Hosp, Div Cardiol, Royal Oak, MI 48072 USA
[2] St Joseph Med Ctr, Div Cardiol, South Bend, IN USA
[3] St Charles Hosp, Div Cardiol, Bend, OR USA
[4] Wausau Hosp, Div Cardiol, Wausau, WI USA
[5] Oulu Univ, Div Cardiol, Oulu, Finland
[6] Henry Ford Hosp, Div Cardiol, Detroit, MI USA
[7] Inst Modelo Cardiol, Div Cardiol, Cordoba, Argentina
[8] Mallinckrodt Inc, St Louis, MO USA
[9] Boston Sci, Maple Grove, MA USA
关键词
D O I
10.1016/S0735-1097(02)01870-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The Air Primary Angioplasty in Myocardial Infarction (PAMI) study was designed to determine the best reperfusion strategy for patients with high-risk acute myocardial infarction (AMI) at hospitals without percutaneous transluminal coronary angioplasty (PTCA) capability. BACKGROUND Previous studies have suggested that high-risk patients have better outcomes with primary PTCA than with thrombolytic therapy. It is unknown whether this advantage would be lost if the patient had to be transferred for PTCA, and reperfusion was delayed. METHODS Patients with high-risk AMI (age >70 years, anterior MI, Killip class II/III, heart rate >100 beats/min or systolic BP <100 mm Hg) who were eligible for thrombolytic therapy were randomized to either transfer for primary PTCA or on-site thrombolysis. RESULTS One hundred thirty-eight patients were randomized before the study ended (71 to transfer for PTCA and 67 to thrombolysis). The time from arrival to treatment was delayed in the transfer group (155 vs. 51 min, p < 0.0001), largely due to the initiation of transfer (43 min) and transport time (26 min). Patients randomized to transfer had a reduced hospital stay (6.1 +/- 4.3 vs. 7.5 +/- 4.3 days, p = 0.015) and less ischemia (12.7% vs. 31.8%, p = 0.007). At 30 days, a 38% reduction in major adverse cardiac events was observed for the transfer group; however, because of the inability to recruit the necessary sample size, this did not achieve statistical significance (8.4% vs. 13.6%, p = 0.331). CONCLUSIONS Patients with high-risk AMI at hospitals without a catheterization laboratory may have an improved outcome when transferred for primary PTCA versus on-site thrombolysis; however, this will require further study. The marked delay in the transfer process suggests a role for triaging patients directly to specialized heart-attack centers. (C) 2002 by the American College of Cardiology Foundation.
引用
收藏
页码:1713 / 1719
页数:7
相关论文
共 41 条
[1]   ADJUNCTIVE THROMBOLYTIC THERAPY DURING ANGIOPLASTY FOR ISCHEMIC REST ANGINA - RESULTS OF THE TAUSA TRIAL [J].
AMBROSE, JA ;
ALMEIDA, OD ;
SHARMA, SK ;
TORRE, SR ;
MARMUR, JD ;
ISRAEL, DH ;
RATNER, DE ;
WEISS, MB ;
HJEMDAHLMONSEN, CE ;
MYLER, RK ;
MOSES, J ;
UNTERECKER, WJ ;
GRUNWALD, AM ;
GARRETT, JS ;
COWLEY, MJ ;
ANWAR, A ;
SOBOLSKI, J .
CIRCULATION, 1994, 90 (01) :69-77
[2]   Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery - A randomized controlled trial [J].
Aversano, T ;
Aversano, LT ;
Passamani, E ;
Knatterud, GL ;
Terrin, ML ;
Williams, DO ;
Forman, SA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (15) :1943-1951
[3]  
Ayres M, 1995, J INVASIVE CARDIOL, V7, pF40
[4]   ACTIVATION OF THE COMPLEMENT-SYSTEM BY RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR [J].
BENNETT, WR ;
YAWN, DH ;
MIGLIORE, PJ ;
YOUNG, JB ;
PRATT, CM ;
RAIZNER, AE ;
ROBERTS, R ;
BOLLI, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 10 (03) :627-632
[5]  
Betriu A, 1997, NEW ENGL J MED, V336, P1621
[6]   Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (Recombinant plasminogen activator) and front-loaded, accelerated alteplase (Recombinant tissue plasminogen activator) in patients with acute myocardial infarction [J].
Bode, C ;
Smalling, RW ;
Berg, G ;
Burnett, C ;
Lorch, G ;
Kalbfleisch, JM ;
Chernoff, R ;
Christie, LG ;
Feldman, RL ;
Seals, AA ;
Weaver, WD .
CIRCULATION, 1996, 94 (05) :891-898
[7]   6-MONTH CLINICAL AND ANGIOGRAPHIC FOLLOW-UP AFTER DIRECT ANGIOPLASTY FOR ACUTE MYOCARDIAL-INFARCTION - FINAL RESULTS FROM THE PRIMARY ANGIOPLASTY REGISTRY [J].
BRODIE, BR ;
GRINES, CL ;
IVANHOE, R ;
KNOPF, W ;
TAYLOR, G ;
OKEEFE, J ;
WEINTRAUB, RA ;
BERDAN, LG ;
TCHENG, JE ;
WOODLIEF, LH ;
CALIFF, RM ;
ONEILL, WW .
CIRCULATION, 1994, 90 (01) :156-162
[8]   Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction [J].
Brodie, BR ;
Stuckey, TD ;
Wall, TC ;
Kissling, G ;
Hansen, CJ ;
Muncy, DB ;
Weintraub, RA ;
Kelly, TA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (05) :1312-1319
[9]   Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial) [J].
Brodie, BR ;
Stone, GW ;
Morice, MC ;
Cox, DA ;
Garcia, E ;
Mattos, LA ;
Boura, J ;
O'Neill, WW ;
Stuckey, TD ;
Milks, S ;
Lansky, AJ ;
Grines, CL .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (10) :1085-1090
[10]  
Brouwer MA, 2001, J AM COLL CARDIOL, V37, p368A